Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (61782)	1/25/2001 3:55:07 PM
From: Mark Adams	Read Replies (5) \| Respond to of 436258

Biopure looks to be short on cash. I see a good portion of the float already short, perhaps in anticipation of this. Floorless convertable on the way? I don't think the public would react to the bovine source aspect, as this type of stuff would likely be used in an ER type setting- massive trauma. And I hear blood is getting harder to come by, now that anyone who has every had beef or beef products, or breathed the air can no longer donate. This one might be playable- no due dilligence done other than a glance at their cash position. PDGM By BridgeNews New York--Dec. 14--Paradigm Genetics Inc., a functional genomics company, and Switzerland's Prionics A.G. will develop and market blood-based diagnostics for the detection of Creutzfeld-Jakob Disease in humans and Bovine Spongiform Encephalopathy, mad cow disease, in cattle. Both firms will share development costs while Paradigm will receive royalties on developed products.